Mechanism
Resolução GECEX nº 855, adopted at the GECEX meeting of 13 February 2026, imposes a definitive antidumping duty for up to five years on hypodermic needles (agulhas hipodérmicas) originating from China. The duty applies to the single NCM tariff code 9018.32.19 ("outras agulhas tubulares de metal" — other tubular metal needles), covering disposable hypodermic needles for human and veterinary injection use that are not otherwise classified in the specific exclusions.
Duty structure: The specific tariff is fixed in US dollars per thousand units of needles. Rates vary by Chinese producer/exporter, with LegisWeb-confirmed rates ranging from USD 0.23 to USD 25.57 per thousand units. Non-cooperating exporters receive the higher residual rate, consistent with GECEX/DECOM standard practice for multi-party investigations. The duty is collected on an ad-valorem specific basis at the Brazilian customs frontier.
Scope exclusions: The following needle categories are explicitly excluded from NCM 9018.32.19 under this resolution:
- Insulin needles (agulhas para insulina)
- Biopsy needles
- Animal insemination needles
- Anesthesia needles
- Bulk non-sterile needles
- Non-hypodermic surgical needles (e.g., suture needles)
The investigation was conducted by DECOM (Departamento de Defesa Comercial) under the authority of Lei nº 9.019/1995 (Brazil's foundational AD/CVD enabling statute, 1995-03-30-brazil-lei-9019-ad-cvd-safeguards-parent) and WTO Anti-Dumping Agreement (Article VI GATT 1994). China is the dominant origin for hypodermic needles imported into Brazil, with an estimated share exceeding 80% of Brazilian imports in 2023-24 per Comex Stat data.
The measure was published in DOU Edição 32 on 18 February 2026 as part of the companion trio with Res 854 (cold-rolled flat steel) and Res 856 (galvanized/coated flat steel), confirming GECEX's practice of batching multiple AD resolutions into single DOU editions.
Downstream implications
- First medical-device trade-remedy on the IPTM register: Res 855 opens the medical-device / disposable-medical-supplies typology on the register. The 2024-2026 Chinese industrial overcapacity wave has reached syringe, needle, IV-equipment, and surgical-supply categories materially affecting Brazilian and EM domestic producers; Res 855 is the first enforcement instrument against this trend.
- Nova Indústria Brasil (NIB) defensive-trade pillar at the medical-supplies HS-code level: The measure operationalises the 2024 NIB framework (
2024-01-22-brazil-nova-industria-brasil-nib) in healthcare supply-chain resilience — strategic post-Covid-19 for Brazilian health-system procurement security. - Brazilian 2025-26 trade-remedy wave extension into medical devices: Res 855 extends the wave beyond upstream steel + chemicals + fibre-optic-cable into downstream medical supplies. Peer instruments filed: Res 765 (carbon-steel sheets, CN), Res 778 (synthetic polyester fibres, CN), Res 829/837 (optical fibre/cable, CN), Res 849 (pre-painted steel, CN+IN), Res 854 (cold-rolled flat steel, CN), Res 856 (galvanized/coated steel, CN — companion DOU Edição 32 publication).
- Canonical template for future medical-supplies AD investigations: Res 855 creates the DECOM investigative template and domestic-industry-petition framework for any subsequent medical-supplies AD probes (sutures, IV catheters, surgical drapes, gloves) as DECOM expands its medical-device enforcement pipeline.
- BD Brasil + domestic producers protected: Brazilian medical-device manufacturers (BD Brasil, Saldanha Rodrigues, Injex) gain protected domestic market share against Chinese-origin hypodermic needle imports. BD Brasil (Becton Dickinson) operates manufacturing facilities in Brazil and has been a major domestic-industry petitioner in global hypodermic needle AD cases.
Open questions
- Exact rate table by named Chinese producer/exporter in the full Article 1 schedule (LegisWeb confirmed USD 0.23–25.57/thousand-units range; individual producer rates not confirmed).
- Whether DECOM will initiate a companion countervailing duty (CVD) investigation against Chinese hypodermic needle subsidies as follow-on enforcement.
- Whether the parallel anti-subsidy investigation against Chinese and Indonesian medical-device producers (referenced in queue notes as an ongoing parallel probe) will yield a separate CVD resolution.
- Downstream cost pass-through to Brazilian SUS (Sistema Único de Saúde) public-health procurement prices for hypodermic needles.